SCHEMBL4309474

SCHEMBL4309474

O=C(Nc1ccccc1)Nc1ccccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.51
SNCA P37840 1/20 0.50
CDK2 P24941 2/20 0.49
FLT3 P36888 2/20 0.49
CCNA2 P20248 1/20 0.49
CCNA1 P78396 1/20 0.49
KDM4E B2RXH2 2/20 0.46
MAPT P10636 1/20 0.46
IDO1 P14902 1/20 0.44
NPC1 O15118 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
FGFR1 P11362 3/20 0.41
PLK4 O00444 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4309480 1.00 KDR (0.51) KDRSNCACDK2FLT3CCNA2
SCHEMBL4315173 0.84 KDR (0.59) KDRSNCACHEK1FGFR1JAK2
SCHEMBL4315179 0.84 KDR (0.59) KDRSNCACHEK1FGFR1JAK2
SCHEMBL4317521 0.84 FGFR1 (0.48) KDRFLT3KDM4EMAPTCHEK1
SCHEMBL4317526 0.84 FGFR1 (0.48) KDRFLT3KDM4EMAPTCHEK1
SCHEMBL4322828 0.84 GAA (0.44) KDRSNCAFLT3KDM4ESMN1; SMN2
SCHEMBL4322819 0.84 GAA (0.44) KDRSNCAFLT3KDM4ESMN1; SMN2
SCHEMBL27711635 0.83 KDR (0.49) KDRCDK2FLT3CCNA2CCNA1
SCHEMBL4309552 0.83 KDR (0.49) KDRCDK2FLT3CCNA2CCNA1
SCHEMBL4308050 0.83 FLT3 (0.58) KDRCDK2FLT3CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDR 75/4885SNCA 4866/4885CDK2 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.